LRRC15 antibody-drug conjugates show promise as ...
LRRC15-targeted antibody-drug conjugates (ADCs) show promise in treating osteosarcoma (OS), with LRRC15-PNU demonstrating superior efficacy over LRRC15-MMAE in inhibiting OS growth in vitro and in vivo. LRRC15 expression, regulated by TGFβ, offers a therapeutic target, especially for high-expressing OS cells, suggesting potential for sensitizing low-expressing cells to ADC treatment.
Related Clinical Trials
Reference News
LRRC15-targeted antibody-drug conjugates (ADCs) show promise in treating osteosarcoma (OS), with LRRC15-PNU demonstrating superior efficacy over LRRC15-MMAE in inhibiting OS growth in vitro and in vivo. LRRC15 expression, regulated by TGFβ, offers a therapeutic target, especially for high-expressing OS cells, suggesting potential for sensitizing low-expressing cells to ADC treatment.